Melanoma/Skin Cancers

Oncoletter provides you with quotes from the abstract's conclusions. To see more, go the ASCO Meeting Library while clicking on the link of the study-titles (to see videos and slides needs a payable registration)  
 
 
Alexander M. Eggermont, Christian U. Blank, Mario Mandalà, et al.
 
The abstract concludes: 
Pembrolizumab, administered at 200 mg every 3 weeks for up to 1 year as adjuvant therapy, provided, at a 3-yr median follow-up, a sustained improvement in RFS, which was clinically meaningful, in resected high-risk stage III melanoma. This improvement was consistent across subgroups. In the overall population, the 3-yr cumulative incidence of distant metastasis being the first recurrence was 22.3% (pembrolizumab group) vs 37.3% (placebo group) (HR 0.55, 95% CI 0.44-0.69). Clinical trial information: NCT02362594
—————————————————————————————————————————————————————————————————————————————
 
 
Axel Hauschild, Reinhard Dummer, Mario Santinami, et al.
 
The abstract concludes: 
This 5-year analysis confirms the long-term benefit of adjuvant D+T in pts with resected stage III BRAFV600E/K–mutant melanoma. Clinical trial information: NCT01682083
—————————————————————————————————————————————————————————————————————————————
 
 
Christian U. Blank, Irene L.M. Reijers, Thomas Pennington, et al.
 
The abstract concludes: 
Neoadj I1N3 treatment induced a high pRR with tolerable toxicity. TLND was omitted in a major subset of pts, reducing surgical morbidity. Longer FU is needed to report safety and RFS when TLND is omitted in MPR pts. Clinical trial information: NCT02977052
—————————————————————————————————————————————————————————————————————————————
 
 
Michael A. Postow, Debra A Goldman, Alexander Noor Shoushtari, et al.
 
The abstract concludes: 
The first 2 doses of nivo + ipi appear to drive combo’s response efficacy and toxicity. Early radiographic imaging at week 6 may be able to identify pts who do not respond to combo dosing beyond dose 2. Randomized studies are planned to evaluate 1 dose of combo to see if efficacy is maintained with reduced toxicity. Clinical trial information: NCT03122522
—————————————————————————————————————————————————————————————————————————————
 
 
Daniel Olson, Jason J. Luke, Andrew Stewart Poklepovic, et al.
 
The abstract concludes: 
This is the largest prospective study of IPI 1mg/kg + PEMBRO, demonstrating significant antitumor activity and tolerability in MEL post-PD1 Ab. Clinical trial information: NCT02743819
—————————————————————————————————————————————————————————————————————————————
 
 
Ines Pires Da Silva, Tasnia Ahmed, Serigne Lo,et al.
 
The abstract concludes: 
In pts resistant to PD1, IPI+PD1 has higher RR, longer survival, yet similar high grade tox than IPI alone. Predictive models of response & survival will help select pts for IPI+/-PD1 after progressing on PD1.
—————————————————————————————————————————————————————————————————————————————
 
 
Amod Sarnaik, Nikhil I. Khushalani, Jason Alan Chesney,et al.
 
The abstract concludes: 
Lifileucel treatment results in a 36.4% ORR and mDOR was not reached at 17.0 months of median study follow up in a heavily pretreated metastatic melanoma patients with high baseline disease burden who progressed on multiple prior therapies, including anti-PD1 and BRAF/MEK inhibitors, if BRAFv600 mutant. Clinical trial information: NCT02360579
—————————————————————————————————————————————————————————————————————————————
 
 
Isabella Claudia Glitza, Suzanne Phillips, Courtney Brown, et al.
 
The abstract concludes: 
The trial demonstrates the feasibility of prospective clinical trials in MM patients with LMD. The combination of IT/ IV N was safe and well-tolerated, with no unexpected systemic or neurological toxicity. Final presentation will include results of LMD composite response assessment, comparative analysis of longitudinal CSF/blood samples to assess immunologic effects. Finally, the interim OS of the patients is encouraging, and supports further evaluation of IT administration of immunotherapy agents for pts with MM and LMD. Clinical trial information: NCT03025256
—————————————————————————————————————————————————————————————————————————————
 
 
DISCUSSANT
Ryan J. Sullivan, MD | Massachusetts General Hospital
 
 
—————————————————————————————————————————————————————————————————————————————
 
Abstract from the clinical science symposium:

10009 Integrative tumor and immune cell multi-omic analyses to predict melanoma response to immune checkpoint blockade.

Valsamo Anagnostou, Daniel C. Bruhm, Noushin Niknafs,et al.

The abstract concludes: 
Our findings highlight the multi-faceted interactions between the tumor and the immune system and the importance of pre-existing T and B cell immunity in driving clinical response and PFS after immune checkpoint blockade, laying the groundwork for integration of genomic and immune features into predictive models that may ultimately optimize therapeutic decisions.
 
See the report in the ASCO DAILY NEWS: 
————————————————————————————————————————————————————————————————————————————
 
MORE ABSTRACTS:
 
Poster Discussion Session
 
Poster Session
 
ASCO Direct™ Focus – ASCO®20 Virtual Program  
Top presentations and expert interviews now available on demand!
Visit ascodirect2020.com and enter the following username „asco“ and password: „oncology"  
ASCO Direct Focus is an officially licensed online program for oncology professionals worldwide, providing complimentary access to an ASCO-curated selection of top presentations from the ASCO20 Virtual Scientific Program, plus expert commentaries.
Melanoma/Skin (Abstracts #10000, 10001, 10002)
Access Content Now